Results 201 to 210 of about 77,069 (259)

Exploitation plan - M20

openaire   +1 more source

Discovery of a Novel MyD88 Inhibitor M20 and Its Protection Against Sepsis-Mediated Acute Lung Injury

Frontiers in Pharmacology, 2021
Myeloid differentiation factor 88 (MyD88) is a hub protein in the Toll-like receptor signaling pathway, which acts as a master switch for numerous inflammatory diseases, including acute lung injury (ALI).
Ximing Xu, Yuepiao Cai
exaly   +2 more sources

The Structural Characterization of Extracellular Polysaccharide from Enterococcus faecium M20

Brazilian Archives of Biology and Technology, 2022
Dicle Arar, Nazime Mercan DoĞan, Yusuf ÖZCAN   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Bioanalytical method validation and sample analysis for nirmatrelvir in dried blood collected using the Tasso-M20 device

Bioanalysis, 2022
Aim: A sensitive and selective method for the determination of nirmatrelvir in dried human blood collected by Tasso-M20 was developed and validated from 20.0 to 20,000 ng/ml. Materials & methods: Nirmatrelvir and its stable-labeled internal standard were
Katty X Wan, Daniel Potts, P. González, I. Smith, Haihong Shi, Olga Kavetska   +5 more
exaly   +2 more sources

Effects of ABCB1 and ABCG2 Polymorphisms on the Pharmacokinetics of Abemaciclib Metabolites (M2, M20, M18)

Anticancer Research, 2023
Background/Aim: Abemaciclib, an oral anticancer drug used in the treatment of breast cancer, is metabolised to its active forms – M2, M20 and M18; these forms have a potency similar to that of the parent drug.
Akimitsu Maeda, Hitoshi Ando, Kei Irie, Naoya Hashimoto, Jun‐ichi Morishige, Shoji Fukushima, H. Ebi, K. Uchida, H. Iwata, M. Sawaki   +9 more
semanticscholar   +1 more source

“A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring”

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022
Abemaciclib (ABEMA) is the last CDKi approved for the treatment of breast cancer. Adverse reactions to this drug are not experienced in the same manner by the entire patient population but in case of severe toxicity dose reductions and therapy ...
Ariana Soledad Poetto, B. Posocco, Martina Zanchetta, S. Gagno, Marco Orleni, Giovanni Canil, M. Alberti, F. Puglisi, G. Toffoli   +8 more
exaly   +2 more sources

K3 surfaces with action of the group M20$M_{20}$

Bulletin of the London Mathematical Society, 2023
It was shown by Mukai that the maximum order of a finite group acting faithfully and symplectically on a K3 surface is 960 and if such a group has order 960, then it is isomorphic to the Mathieu group M20$M_{20}$ .
Paola Comparin, Romain Demelle
semanticscholar   +1 more source

Pathogenic Acanthamoeba castellanii Secretes the Extracellular Aminopeptidase M20/M25/M40 Family Protein to Target Cells for Phagocytosis by Disruption

Molecules, 2017
Acanthamoeba is free-living protist pathogen capable of causing a blinding keratitis and granulomatous encephalitis. However, the mechanisms of Acanthamoeba pathogenesis are still not clear.
Lih-Ren Chen, Wei-Chen Lin, Lynn L H Huang   +2 more
exaly   +2 more sources

Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.

Journal of Pharmaceutical and Biomedical Analysis, 2022
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib were approved by the U.S. Food and Drug Administration (FDA) and European Medicine Agency for the treatment of breast cancer between 2015 and 2018.
Katharina Habler, Anne-Sophie Kalla, M. Rychlik, M. Vogeser, D. Teupser   +4 more
semanticscholar   +1 more source